menu
    • menu

    Company profile for Mediar Therapeutics

    NEW Drugs in Dev: 2
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Mediar is a preclinical stage biotechnology company developing therapeutics to halt, or even reverse, fibrosis. The platform and pipeline are based on an emerging class of novel targets – fibrotic mediators – that play key roles in modulating myofibroblast biology and the development of fibrosis in chronically damaged organs. Mediar’s foundational technology is based on pioneering research from Massachusetts General Ho...
    Mediar is a preclinical stage biotechnology company developing therapeutics to halt, or even reverse, fibrosis. The platform and pipeline are based on an emerging class of novel targets – fibrotic mediators – that play key roles in modulating myofibroblast biology and the development of fibrosis in chronically damaged organs. Mediar’s foundational technology is based on pioneering research from Massachusetts General Hospital and Brigham and Women's Hospital. The company was founded by Partners Innovation Fund in 2018 and is located at Lab Central, Cambridge’s premier biotechnology incubator.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Mediar TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    700 Main Street, North Cambridge, MA 02139
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.mediartx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/mediar-therapeutics/about/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    euroPLX 90 Lisbon

    Not Confirmed

    envelop Contact Supplier

    euroPLX 90 Lisbon

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Alloy Speeds Complex Fibrosis Targets Toward Clinical Trials
    Alloy Speeds Complex Fibrosis Targets Toward Clinical Trials

    03 Feb 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-02-03/alloy-accelerates-mediar-timeline-to-the-clinic-for-complex-fibrosis-targets

    PHARMIWEB
    03 Feb 2026
    Share Share
    Mediar Therapeutics Secures $76M Series B Funding
    Mediar Therapeutics Secures $76M Series B Funding

    07 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mediar-therapeutics-announces-oversubscribed-76-million-series-b-financing-and-clinical-advancement-of-first-in-class-fibrosis-portfolio-302654321.html

    PR NEWSWIRE
    07 Jan 2026
    Share Share
    Mediar Therapeutics Doses First Patient in Phase 2 WISPer Trial o
    Mediar Therapeutics Doses First Patient in Phase 2 WISPer Trial o

    05 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mediar-therapeutics-doses-first-patient-in-phase-2-wisper-trial-of-mtx-463-for-idiopathic-pulmonary-fibrosis-302473778.html

    PR NEWSWIRE
    05 Jun 2025
    Share Share
    Mediar, Lilly License Antibody for Idiopathic Pulmonary Fibrosis
    Mediar, Lilly License Antibody for Idiopathic Pulmonary Fibrosis

    10 Jan 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mediar-therapeutics-enters-into-global-licensing-agreement-with-lilly-to-advance-first-in-class-wisp1-antibody-for-the-treatment-of-idiopathic-pulmonary-fibrosis-ipf-302347905.html

    PR NEWSWIRE
    10 Jan 2025
    Share Share
    Mediar Therapeutics Initiates Second Clinical Program
    Mediar Therapeutics Initiates Second Clinical Program

    07 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mediar-therapeutics-initiates-second-clinical-program-in-portfolio-of-novel-first-in-class-antibodies-designed-to-halt-fibrosis-302215886.html

    PR NEWSWIRE
    07 Aug 2024
    Share Share
    Mediar begins patient dosing in US FDA approved phase 1 trial of MTX-463
    Mediar begins patient dosing in US FDA approved phase 1 trial of MTX-463

    07 May 2024

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=168956&sid=2

    PHARMABIZ
    07 May 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search